RC
PASG icon

RBF Capital’s Passage Bio PASG Stock Holding History

RBF Capital’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,140
Closed -$57.2K – 612
2025
Q2 		$57.2K Hold
7,140
– – ﹤0.01% 591
2025
Q1 		$50.4K Hold
7,140
– – ﹤0.01% 563
2024
Q4 		$81K Hold
7,140
– – ﹤0.01% 532
2024
Q3 		$100K Hold
7,140
– – 0.01% 578
2024
Q2 		$113K Hold
7,140
– – 0.01% 548
2024
Q1 		$193K Hold
7,140
– – 0.01% 514
2023
Q4 		$144K Hold
7,140
– – 0.01% 512
2023
Q3 		$94K Hold
7,140
– – 0.01% 511
2023
Q2 		$134K Buy
7,140
+1,600
+29% +$31.7K 0.01% 489
2023
Q1 		$106K Sell
5,540
-170
-3% -$4.61K 0.01% 484
2022
Q4 		$158K Hold
5,710
– – 0.01% 475
2022
Q3 		$143K Hold
5,710
– – 0.01% 481
2022
Q2 		$270K Buy
+5,710
New +$267K 0.02% 433

Other funds holding PASG

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RBF Capital's PASG Position: Q3 2025 in Review

RBF Capital sold out of Passage Bio (PASG) in Q3 2025, closing a stake of 7,140 shares — an estimated $57.2K sold.

RBF Capital first reported a position in PASG in Q2 2022 and held it in 13 quarters. The position peaked at $270K in Q2 2022. 32 funds tracked by Wall St. Rank hold PASG as of Q3 2025.

  • RBF Capital reported no remaining Passage Bio position as of Q3 2025 after selling out during the quarter.
  • RBF Capital sold 7,140 Passage Bio shares in Q3 2025, an estimated $57.2K.
  • RBF Capital first reported a position in Passage Bio in Q2 2022 and held it in 13 quarters.
  • RBF Capital's Passage Bio position peaked at $270K in Q2 2022.
  • 32 funds tracked by Wall St. Rank held Passage Bio as of Q3 2025.

Based on RBF Capital's 13F filing for Q3 2025, filed 14 Nov 2025.